Evidence map›Paper›PMID 38975257›Full record

ReviewThe journal of allergy and clinical immunology. Global2024

Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI).

Fernando Monteiro Aarestrup, Ernesto Akio Taketomi, Clóvis Eduardo Santos Galvão, Gil Bardini Alves, Geórgia Véras de Araújo Gueiros Lira, Marcos Reis Gonçalves, Mariana Graça Couto Miziara, Sidney Souteban Maranhão Casado, Veridiana Aun Rufino Pereira, Dirceu Solé and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of allergy and clinical immunology. Global, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fernando Monteiro AarestrupUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Ernesto Akio TaketomiUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Clóvis Eduardo Santos GalvãoUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Gil Bardini AlvesUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Geórgia Véras de Araújo Gueiros LiraUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Marcos Reis GonçalvesUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Mariana Graça Couto MiziaraUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Sidney Souteban Maranhão CasadoUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Veridiana Aun Rufino PereiraUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Dirceu SoléUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Ekaterini Simoes GoudourisUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Fabio Chigres KuschnirUniversidade Federal de Juiz de Fora, Juiz de Fora, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of allergen immunotherapy (AIT) in Brazil has specific regional conditions owing to the pattern of allergen sensitization, as well as to genetic, socioeconomic, and cultural characteristics. This review article aims to discuss the clinical practice of AIT by the subcutaneous or sublingual route in Brazil, addressing the possibilities of transition between these forms of administration. A systematic review using the PubMed and Cochrane databases was performed, and the websites of major allergy and immunology organizations were consulted. Knowledge of the mechanism of action of subcutaneous immunotherapy and sublingual immunotherapy, together with Brazilian real-life experience, allowed us to establish recommendations regarding switching routes of AIT administration in selected cases. Careful analysis of each clinical situation is necessary to perform the transition between subcutaneous and sublingual allergen immunotherapy.

Indexed as

AIT routesSCITSLITsubcutaneous allergen immunotherapysublingual allergen immunotherapy

Identifiers

PMID38975257
PMCPMC11226966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.